Cited by 247Reproductive Health and ContraceptionEstrogen and related hormone effectsMenopause: Health Impacts and Treatments

The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.

Characteristics and metabolic effects of estrogen and progestins contained in oral contraceptive pills

Sitruk-Ware, Regine, Nath, Anita·2013·Best Practice & Research Clinical Endocrinology & Metabolism

DOI 10.1016/j.beem.2012.09.004

Open this paper in CoChat — free account

Abstract

Estrogen and progestins have been used by millions of women as effective combined oral contraceptives. Oral contraceptives (OCs) modify surrogate markers such as lipoproteins, insulin response to glucose, and coagulation factors, that have been associated with cardiovascular and venous risk. Ethinyl-Estradiol (EE) exerts a stronger effect that natural estradiol (E2) on hepatic metabolism. New progestins with high specificity have been designed to avoid interaction with other receptors and prevent androgenic, estrogenic or glucocorticoid related side-effects. The risks and benefits of new progestins used in contraception depend upon their molecular structure, the type and dose of associated estrogen, and the delivery route. The lower impact of E2-based combinations on metabolic surrogate markers may result in an improved safety profile, but only clinical outcomes are relevant to assess the risk. Large surveillance studies are warranted to confirm this hypothesis.

Integrity signals

Registry

Crossref · 10.1016/j.beem.2012.09.004

Cites

79 of 79 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

National Center for Health Statistics (NCHS)
Feinleib, M. (2005) · Encyclopedia of Biostatistics · doi:10.1002/0470011815.b2a16042 · Cited by 3,134
Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes.
Guilherme, A., Virbasius, J. V., Puri, V., & Czech, M. P. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2391 · Cited by 2,292
Trends in the Incidence of Venous Thromboembolism during Pregnancy or Postpartum: A 30-Year Population-Based Study
Heit, J. A., Kobbervig, C. E., James, A., Petterson, T. M., Bailey, K. R., & Melton, L. J. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-10-200511150-00006 · Cited by 1,336
Fertility, family planning, and reproductive health of U.S. women: Data from the 2002 National Survey of Family Growth
Chandra, A., Martinez, G. M., Mosher, W. D., Abma, J. C., & Jones, J. (2005) · PsycEXTRA Dataset · doi:10.1037/e414702008-001 · Cited by 957
Classification and pharmacology of progestins
Schindler, A. E., Campagnoli, C., Druckmann, R. A., Huber, J. C., Pasqualini, J. R., Schweppe, K.-W., & Thijssen, J. H. H. (2003) · Maturitas · doi:10.1016/j.maturitas.2003.09.014 · Cited by 741
Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9
Lidegaard, O., Nielsen, L. H., Skovlund, C. W., Skjeldestad, F. E., & Lokkegaard, E. (2011) · BMJ · doi:10.1136/bmj.d6423 · Cited by 608
The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance study on Oral Contraceptives based on 142,475 women-years of observation
Dinger, J. C., Heinemann, L. A. J., & Kühl-Habich, D. (2007) · Contraception · doi:10.1016/j.contraception.2006.12.019 · Cited by 472
The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism
Godsland, I. F., Crook, D., Simpson, R., Proudler, T., Felton, C., Lees, B., Anyaoku, V., Devenport, M., & Wynn, V. (1990) · New England Journal of Medicine · doi:10.1056/nejm199011153232003 · Cited by 417
McARDLE'S SYNDROME
Mellick, R. S., Mahler, R., & Hughes, B. P. (1962) · The Lancet · doi:10.1016/s0140-6736(62)92145-1 · Cited by 390
Factors Associated with Contraceptive Choice and Inconsistent Method Use, United States, 2004
Frost, J. J., & Darroch, J. E. (2008) · Perspectives on Sexual and Reproductive Health · doi:10.1363/4009408 · Cited by 381
New progestagens for contraceptive use
Sitruk-Ware, R. L. (2005) · Human Reproduction Update · doi:10.1093/humupd/dmi046 · Cited by 376
Drospirenone: pharmacology and pharmacokinetics of a unique progestogen
Krattenmacher, R. (2000) · Contraception · doi:10.1016/s0010-7824(00)00133-5 · Cited by 375
Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10
Lidegaard, O., Nielsen, L. H., Skovlund, C. W., & Lokkegaard, E. (2012) · BMJ · doi:10.1136/bmj.e2990 · Cited by 326
Comparison of pharmacodynamic properties of various estrogen formulations
Mashchak, C. A., Lobo, R. A., Dozono-Takano, R., Eggena, P., Nakamura, R. M., Brenner, P. F., & Mishell, D. R. (1982) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(82)90218-6 · Cited by 316
Insulin resistance, secretion, and metabolism in users of oral contraceptives
Godsland, I. F., Walton, C., Felton, C. V., Proudler, A. J., Patel, A., & Wynn, V. (1992) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.74.1.1530790 · Cited by 254
Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data
Jick, S. S., & Hernandez, R. K. (2011) · BMJ · doi:10.1136/bmj.d2151 · Cited by 236
Biological Effects of Estradiol-17β in Postmenopausal Women: Oral Versus percutaneous Administration
LIGNIERS, B. D., Basdevant, A., Thomas, G., Thalabard, J., Mercier-Bodard, C., Conard, J., Guyene, T.-T., MAIRON, N., Corvol, P. L., Guy-grand, B., et al. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-62-3-536 · Cited by 228
Reprint of Classification and pharmacology of progestins
Schindler, A. E., Campagnoli, C., Druckmann, R. A., Huber, J. C., Pasqualini, J. R., Schweppe, K.-W., & Thijssen, J. H. H. (2008) · Maturitas · doi:10.1016/j.maturitas.2008.11.013 · Cited by 224
Effects on Coagulation of Levonorgestrel- and Desogestrel-containing Low Dose Oral Contraceptives: a Cross-over Study
Meijers, J. C. M., van den Ende, A., van Enk, A., Bouma, B. N., Tans, G., Rosing, J., Prins, M. H., Buller, H. R., & Middeldorp, S. (2000) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1613958 · Cited by 217
Pharmacokinetics of oestrogens and progestogens
Kühl, H. (1990) · Maturitas · doi:10.1016/0378-5122(90)90003-o · Cited by 200
COMPARISON OF EFFECTS OF DIFFERENT COMBINED ORAL-CONTRACEPTIVE FORMULATIONS ON CARBOHYDRATE AND LIPID METABOLISM
Wynn, V., Godsland, I., Niththyananthan, R., ADAMS, P. W., Melrose, J., Oakley, N. W., & Seed, M. (1979) · The Lancet · doi:10.1016/s0140-6736(79)92949-0 · Cited by 196
Nestorone®: a progestin with a unique pharmacological profile
Kumar, N. (2000) · Steroids · doi:10.1016/s0039-128x(00)00119-7 · Cited by 184
Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile
Sasagawa, S., Shimizu, Y., Kami, H., Takeuchi, T., Mita, S., Imada, K., Kato, S., & Mizuguchi, K. (2008) · Steroids · doi:10.1016/j.steroids.2007.10.003 · Cited by 177
The use of newer progestins for contraception
Sitruk-Ware, R. L., & Nath, A. (2010) · Contraception · doi:10.1016/j.contraception.2010.04.004 · Cited by 173
Comparative Pharmacology of Newer Progestogens
Kühl, H. (1996) · Drugs · doi:10.2165/00003495-199651020-00002 · Cited by 171
Progesterone receptor knockout mice have an improved glucose homeostasis secondary to β-cell proliferation
Picard, F., Wanatabe, M., Schoonjans, K., Lydon, J. P., O’Malley, B. W., & Auwerx, J. H. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202612199 · Cited by 160
Coactivator/corepressor ratios modulate PR-mediated transcription by the selective receptor modulator RU486
Liu, Z., Auboeuf, D., Wong, J., Chen, J. D., Tsai, S. Y., Tsai, M., & O’Malley, B. W. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.122225699 · Cited by 159
Progestogen-only contraception in women at high risk of venous thromboembolism
Conard, J., Plu‐Bureau, G., Bahi, N., Horellou, M., Pelissier, C., & Thalabard, J. (2004) · Contraception · doi:10.1016/j.contraception.2004.07.009 · Cited by 137
Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic–pituitary–ovarian activity
Edelman, A. B., Carlson, N. E., Cherala, G., Munar, M. Y., Stouffer, R. L., Cameron, J. L., Stanczyk, F. Z., & Jensen, J. T. (2009) · Contraception · doi:10.1016/j.contraception.2009.04.011 · Cited by 132
Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol compared with one containing levonorgestrel and ethinylestradiol on haemostasis, lipids and carbohydrate metabolism
Ågren, U. M., Anttila, M., Mäenpää-Liukko, K., Rantala, M.-L., Rautiainen, H., Sommer, W. F., & Mommers, E. (2011) · The European Journal of Contraception & Reproductive Health Care · doi:10.3109/13625187.2011.604450 · Cited by 130
Oral progestogen-only contraceptives and cardiovascular risk: Results from the Transnational Study on Oral Contraceptives and the Health of Young Women
Heinemann, L. A. J., Assmann, A., DoMinh, T., & Garbe, E. (1999) · The European Journal of Contraception & Reproductive Health Care · doi:10.3109/13625189909064007 · Cited by 126
Estetrol review: profile and potential clinical applications
Bennink, H. J. T. C., Holinka, C. F., & Diczfalusy, E. R. (2008) · Climacteric · doi:10.1080/13697130802073425 · Cited by 121
Pharmacokinetics and Potency of Progestins used for Hormone Replacement Therapy and Contraception
Stanczyk, F. Z. (2002) · Reviews in Endocrine and Metabolic Disorders · doi:10.1023/a:1020072325818 · Cited by 108
Metabolic and Haemostatic Effects of Estradiol Valerate/Dienogest, a Novel Oral Contraceptive: A Randomized, Open-Label, Single-Centre Study
Junge, W., Mellinger, U., Parke, S., & Serrani, M. (2011) · Clinical Drug Investigation · doi:10.2165/11590220-000000000-00000 · Cited by 107
Formation of Ethinyl Estradiol in Women during Treatment with Norethindrone Acetate
Chu, M. C., Zhang, X., Gentzschein, E., Stanczyk, F. Z., & Lobo, R. A. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0044 · Cited by 100
Comparison of hepatic impact of oral and vaginal administration of ethinyl estradiol
Goebelsmann, U., Mashchak, C. A., & Mishell, D. R. (1985) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(85)90664-7 · Cited by 99
Pharmacokinetic and pharmacological features of oestradiol valerate
Düsterberg, B., & Nishino, Y. (1982) · Maturitas · doi:10.1016/0378-5122(82)90064-0 · Cited by 99
Effects of Oral and Transvaginal Ethinyl Estradiol on Hemostatic Factors and Hepatic Proteins in a Randomized, Crossover Study
Sitruk-Ware, R. L., Plu‐Bureau, G., Ménard, J., Conard, J., Kumar, S., Thalabard, J., Tokay, B. A., & Bouchard, P. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0026 · Cited by 97
Nestorone®: clinical applications for contraception and HRT
Sitruk-Ware, R. L., Small, M., Kumar, N., Tsong, Y. Y., Sundaram, K., & Jackanicz, T. M. (2003) · Steroids · doi:10.1016/s0039-128x(03)00140-5 · Cited by 90
Efficacy and safety of a novel oral contraceptive based on oestradiol (oestradiol valerate/dienogest): A Phase III trial
Palacios, S., Wildt, L., Parke, S., Machlitt, A., Römer, T., & Bitzer, J. (2009) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2009.11.001 · Cited by 85
Effect of four oral contraceptives on hemostatic parameters
Wiegratz, I., Lee, J. H., Kutschera, E., Winkler, U. H., & Kühl, H. (2004) · Contraception · doi:10.1016/j.contraception.2004.03.004 · Cited by 85
Nomegestrol acetate, a novel progestogen for oral contraception
Mueck, A. O., & Sitruk-Ware, R. L. (2011) · Steroids · doi:10.1016/j.steroids.2011.02.002 · Cited by 84
Different effects of oral contraceptives containing different progestogens on protein S and tissue factor pathway inhibitor
van Vliet, H. A. A. M., Bertina, R. M., Dahm, A. E. A., Rosendaal, F. R., Rosing, J., Sandset, P. M., & Helmerhorst, F. M. (2008) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02863.x · Cited by 82
Progestins and Antiprogestins in Clinical Practice
Sitruk-Ware, L. R., & Mishell, D. R. (1999) · Medical Entomology and Zoology · Cited by 72
A comparative study of the effects of the hemostatic system of two monophasic gestodene oral contraceptives containing 20 μg and 30 μg ethinylestradiol
Winkler, U. H., SCHINDLER, A., Endrikat, J., & Düsterberg, B. (1996) · Contraception · doi:10.1016/0010-7824(95)00271-5 · Cited by 71
A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles
Gaspard, U., Endrikat, J., Desager, J. P., Buicu, C., Gerlinger, C., & Heithecker, R. (2004) · Contraception · doi:10.1016/j.contraception.2003.11.003 · Cited by 70
Enhanced Hepatic Extraction of Estrogens Used for Replacement Therapy*
Steingold, K. A., Cefalu, W. T., Pardridge, W. M., Judd, H. L., & Chaudhuri, G. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-62-4-761 · Cited by 67
Pharmacology of the Contraceptive Steroids
Goldzieher, J. W., & Fotherby, K. (1994) · The Endocrinologist · doi:10.1097/00019616-199411000-00011 · Cited by 64
Pharmacokinetics of an oral contraceptive containing oestradiol valerate and dienogest
Zeun, S., Lu, M. Q., Uddin, A., Zeiler, B. N., Morrison, D., & Blode, H. (2009) · The European Journal of Contraception & Reproductive Health Care · doi:10.1080/13625180902850039 · Cited by 64
Different effects of oral contraceptives containing different progestogens on protein S and tissue factor pathway inhibitor
van Vliet, H. A. A. M., Bertina, R. M., Dahm, A. E. A., et al. (2008) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2008.02863.x · Cited by 63
One year contraception with a single subdermal implant containing nomegestrol acetate (uniplant)
Coutinho, E. M. (1993) · Contraception · doi:10.1016/0010-7824(93)90112-k · Cited by 60
Ovulation inhibition by estetrol in an in vivo model
Bennink, H. J. T. C., Skouby, S. O., Bouchard, P., & Holinka, C. F. (2008) · Contraception · doi:10.1016/j.contraception.2007.11.014 · Cited by 60
Effects of nomegestrol acetate (5 mg/d) on hormonal, metabolic and hemostatic parameters in premenopausal women
Basdevant, A., Pelissier, C., Conard, J., Degrelle, H., Guyene, T. T., & Thomas, J.-L. (1991) · Contraception · doi:10.1016/0010-7824(91)90080-y · Cited by 58
The hormonal profile of norethindrone acetate: Rationale for add-back therapy with gonadotropin-releasing hormone agonists in women with endometriosis
Chwalisz, K., Surrey, E., & Stanczyk, F. Z. (2012) · Reproductive Sciences · doi:10.1177/1933719112438061 · Cited by 58
Route of administration of contraceptives containing desogestrel/etonorgestrel and insulin sensitivity: a prospective randomized study
Cagnacci, A., Ferrari, S., Tirelli, A., Zanin, R., & Volpe, A. (2009) · Contraception · doi:10.1016/j.contraception.2009.01.012 · Cited by 50
Effect of dienogest-containing oral contraceptives on lipid metabolism
Wiegratz, I., Lee, J. H., Kutschera, E., Bauer, H., Hayn, C., Moore, C., Mellinger, U., Winkler, U. H., Gross, W., & Kühl, H. (2002) · Contraception · doi:10.1016/s0010-7824(01)00310-9 · Cited by 49
Clinical applications for estetrol
de Visser, M., & Bennink, H. J. T. C. (2009) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2008.12.013 · Cited by 48
Comparative effects of a contraceptive vaginal ring delivering a nonandrogenic progestin and continuous ethinyl estradiol and a combined oral contraceptive containing levonorgestrel on hemostasis variables
Rad, M., Kluft, C., Ménard, J., Burggraaf, J., de Kam, M. L., Meijer, P., Sivin, I., & Sitruk-Ware, R. L. (2006) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2005.12.007 · Cited by 46
Nonoral Routes of Estrogen Administration
Cedars, M. I., & Judd, H. L. (1987) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/s0889-8545(21)00583-0 · Cited by 45
Evaluation of a new estradiol oral contraceptive: estradiol valerate and dienogest
Jensen, J. T. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656561003724713 · Cited by 45
A pharmacokinetic study with a low-dose oral contraceptive containing 20 μg ethinylestradiol plus 100 μg levonorgestrel
Endrikat, J., Blode, H., Gerlinger, C., Rosenbaum, P., & Kuhnz, W. (2002) · The European Journal of Contraception & Reproductive Health Care · doi:10.1080/ejc.7.2.79.90 · Cited by 45
A prospective study on the effects on hemostasis of two oral contraceptives containing drospirenone in combination with either 30 or 20 μg ethinyl estradiol and a reference containing desogestrel and 30 μg ethinyl estradiol
Kluft, C., Endrikat, J., Mulder, S. M., Gerlinger, C., & Heithecker, R. (2005) · Contraception · doi:10.1016/j.contraception.2005.09.015 · Cited by 40
Combined oral contraceptives, venous thromboembolism, and the problem of interpreting large but incomplete datasets
Dinger, J., & Shapiro, S. (2011) · Journal of Family Planning and Reproductive Health Care · doi:10.1136/jfprhc-2011-100260 · Cited by 39
Insulin sensitivity is decreased in normal women by doses of ethinyl estradiol used in oral contraceptives
Kojima, T., Lindheim, S. R., Duffy, D. M., Vijod, M. A., Stanczyk, F. Z., & Løbo, R. A. (1993) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(93)90432-i · Cited by 38
Preclinical evaluation of norgestimate, a progestin with minimal androgenic activity
Phillips, A., Hahn, D. W., & McGuire, J. L. (1992) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(12)90410-x · Cited by 36
Gastrointestinal metabolism of contraceptive steroids
Back, D. J., Madden, S., & Orme, M. L. (1990) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(90)90554-k · Cited by 32
Enzyme immunoassay for nomegestrol acetate in human plasma
Ezan, É., Bénech, H., Bucourt, R., Ardouin, T., Tchernatinsky, C., Thomas, J.-L., Pâris, J., & Grognet, J. (1993) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(93)90105-6 · Cited by 30
Effects of conventional or extended-cycle regimen of an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on various hemostasis parameters
Wiegratz, I., Stahlberg, S., Manthey, T., Sänger, N., Mittmann, K., Lange, E., Mellinger, U., & Kühl, H. (2008) · Contraception · doi:10.1016/j.contraception.2008.06.015 · Cited by 30
Low-dose contraceptive estrogen-progestin and coronary artery atherosclerosis of monkeys
Adams, M. R. (2000) · Obstetrics and Gynecology · doi:10.1016/s0029-7844(00)00891-7 · Cited by 26
Bioequivalence assessment of three different estradiol formulations in postmenopausal women in an open, randomized, single-dose, 3-way cross-over study
Timmer, C. J., & Geurts, T. B. P. (1999) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/bf03190010 · Cited by 26
Nomenclature of the gonane progestins
Edgren, R. A., & Stanczyk, F. Z. (1999) · Contraception · doi:10.1016/s0010-7824(99)00101-8 · Cited by 22
Influence of a new oral contraceptive with drospirenone on lipid metabolism
Taneepanichskul, S., & Phupong, V. (2007) · Gynecological Endocrinology · doi:10.1080/09513590701325731 · Cited by 20
Pharmacology of the Contraceptive Steroids
Mccombs, J. (1995) · Annals of Pharmacotherapy · doi:10.1177/106002809502900226 · Cited by 19
Pharmacokinetics of desogestrel
McClamrock, H. D., & Adashi, E. Y. (1993) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(93)90332-d · Cited by 17
Effects of Contraceptive Estrogen and Progestin on the Atherogenic Potential of Plasma LDLs in Cynomolgus Monkeys
Manning, J. M., Edwards, I. J., Wagner, W. D., Wagner, J. D., Adams, M. R., & Parks, J. S. (1997) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.17.7.1216 · Cited by 16
Human pharmacokinetics of ethynyl estradiol 3-sulfate and 17-sulfate
Goldzieher, J. W., Mileikowsky, G. N., Newburger, J., Dorantes, A., & Stavchansky, S. A. (1988) · Steroids · doi:10.1016/0039-128x(88)90185-7 · Cited by 15
Hormonal contraception: present and future
Benagiano, G., Bastianelli, C., & Farris, M. (2008) · Drugs of today · doi:10.1358/dot.2008.44.12.1299292 · Cited by 12
Metabolism of the oral contraceptive steroids ethynylestradiol, norgestimate and 3-ketodesogestrel by a human endometrial cancer cell line (HEC-1A) and endometrial tissue in vitro
Wild, M. J., Rudland, P. S., & Back, D. J. (1993) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(93)90010-t · Cited by 10
Venous Thrombosis in Users of Non-Oral Hormonal Contraception: Follow-Up Study, Denmark 2001-10
Lidegaard, Ø., Nielsen, L. H., & Skovlund, C. W. (2012) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2012.08.056 · Cited by 8

Flagged first, then by citations

Research works printed but not linked: 1

Parke, 2008, Oral comparative effects of a four-phasic regimen of estradiol valerate/dienogest versus ethinylestradiol/levonorgestrel on haemostatic parameters, Human Reproduction, 23, i77

Sorted by citations

National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2
Jacobson, T. A., Maki, K. C., Orringer, C. E., Jones, P. H., Kris-Etherton, P., Sikand, G., La Forge, R., Daniels, S. R., Wilson, D. P., Morris, P. B., et al. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.09.002 · Cited by 784
“A controlled feeding study conducted by Maki et al.56 evaluated the effects of a PUFA-rich corn oil and a MUFA-rich extra-virgin olive oil (4 tablespoons/day were incorporated into foods) as part of a weight maintenance diet (34% of energy from fat, w8% from saturated fatty acids) on lipids and lipoproteins in men and…”
BackgroundInfluential
The polycystic ovary syndrome: a position statement from the European Society of Endocrinology
Conway, G., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Franks, S., Gambineri, A., Kelestimur, F., Macut, D., Micic, D., Pasquali, R., et al. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0253 · Cited by 676
Sex differences in lipids: a life course approach
Holven, K. B., & Roeters van Lennep, J. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.117270 · Cited by 180
Treatment strategies for women with polycystic ovary syndrome
Jin, P., & Xie, Y. (2017) · Gynecological Endocrinology · doi:10.1080/09513590.2017.1395841 · Cited by 181
“Some studies have found that ethinylestradiol has stronger effects on liver metabolism than natural estradiol, including the synthesis of SHBG, angiotensin, and some blood coagulation factors dependent on estrogen [22].”
Background
Cross-Sex Hormonal Treatment and Body Uneasiness in Individuals with Gender Dysphoria
Fisher, A. D., Castellini, G., Bandini, E., Casale, H., Fanni, E., Benni, L., Ferruccio, N., Meriggiola, M. C., Manieri, C., Gualerzi, A., et al. (2013) · The Journal of Sexual Medicine · doi:10.1111/jsm.12413 · Cited by 147

See all 247

Authors: Sitruk-Ware, R., & Nath, A.
Affiliations: Population Council (US)
Corresponding author: Sitruk-Ware, Regine
ORCID: Sitruk-Ware, Regine
Nath, Anita
Venue: Best Practice & Research Clinical Endocrinology & Metabolism
Publisher: Elsevier BV
Published: 2013-02
Volume: 27
Issue: 1
Pages: 13-24
ISSN: 1521-690X (ISSN-L)
DOI: 10.1016/j.beem.2012.09.004
OpenAlex: W2101802759
Cited by: 247
References: 79
Citations by year: 2026: 14 · 2025: 17 · 2024: 23 · 2023: 45 · 2022: 18 · 2021: 24 · 2020: 22 · 2019: 19 · 2018: 9 · 2017: 12 · 2016: 12 · 2015: 12 · 2014: 17 · 2013: 3
FWCI: 1.58
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: Best Practice & Research Clinical Endocrinology & Metabolism (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Reproductive Health and Contraception
Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
Keywords: oral contraceptives, ethinyl estradiol, progestins, hepatic metabolism, lipoproteins, insulin response, coagulation factors, cardiovascular risk, venous thromboembolism, contraceptive safety
MeSH terms: Contraceptives, Oral, Hormonal, Estrogens, Female, Humans, Progestins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Characteristics and metabolic effects of estrogen and progestins contained in oral contraceptive pills

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks